Trevi Therapeutics Inc (NASDAQ:TRVI) Given $16.75 Consensus Price Target by Brokerages

Trevi Therapeutics Inc (NASDAQ:TRVI) has received a consensus broker rating score of 1.25 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.

Analysts have set a 12-month consensus target price of $16.75 for the company and are predicting that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Trevi Therapeutics an industry rank of 72 out of 256 based on the ratings given to its competitors.

A number of brokerages recently weighed in on TRVI. BMO Capital Markets started coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They issued an “outperform” rating and a $15.00 price target on the stock. Leerink Swann began coverage on shares of Trevi Therapeutics in a research note on Monday, June 3rd. They issued an “outperform” rating for the company. Needham & Company LLC began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They set a “buy” rating and a $18.00 price objective for the company. Stifel Nicolaus began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They issued a “buy” rating and a $20.00 target price for the company. Finally, Svb Leerink began coverage on shares of Trevi Therapeutics in a research report on Monday, June 3rd. They issued an “outperform” rating and a $14.00 target price for the company.

NASDAQ:TRVI traded up $0.09 during mid-day trading on Monday, reaching $7.64. 2,670 shares of the company were exchanged, compared to its average volume of 89,511. Trevi Therapeutics has a 12 month low of $7.18 and a 12 month high of $10.62.

In related news, insider Jennifer L. Good purchased 11,250 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was acquired at an average price of $10.00 per share, with a total value of $112,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anne Vanlent purchased 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was bought at an average cost of $10.00 per share, with a total value of $50,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 391,250 shares of company stock valued at $3,912,500.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

See Also: Quiet Period Expirations Explained

Get a free copy of the Zacks research report on Trevi Therapeutics (TRVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit